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Introduction
Chronic recurrent multifocal osteomyelitis (CRMO) is a
rare autoinflammatory disorder which affects predomi-
nantly girls with peak onset between ages of 7 to 12
years. There is a frequent association of CRMO with
inflammatory skin or gut disorders. Patients with iso-
lated CRMO are usually treated with nonsteroidal anti-
inflammatory drugs (NSAIDs) prior to escalation to cor-
ticoids and disease-modifying antirheumatic drugs such
as methotrexate (MTX), sulfasalazine, azathioprine.
Recently, TNF inhibitors and bisphosphonates have
been recommended for treatment of most severe cases.
Objectives
To evaluate pamidronate treatment in patients with
isolated CRMO relapsing despite NSAID, corticosteroid
and methotrexate therapy in a retrospective study of a
case series.
Methods
Since 2011, 4 patients (3 girls and 1 boy) with CRMO
have been treated with pamidronate in Paediatric
Department of University Hospital Brno, Czech Repub-
lic. All these patients had chronic relapsing multifocal
osteomyelitis without any associated inflammatory con-
dition. The diagnosis of CRMO was set in the mean age
of 12 years based on radiographic findings (x-ray, CT,
MRI) and histological findings of a non-bacterial inflam-
matory bone lesion. Previous treatment with NSAIDs,
corticosteroids, and MTX (MTX used only in 3 of 4
cases) was insufficient.
Results
Intravenous pamidronate administered every 3 to 6
months was added to MTX in 3 patients, in the fourth
case it was started in a MTX naive patient. Corticoster-
oids were used to control acute symptoms. All the
patients with pamidronate significantly improved. In 3
patients including 1 patient without MTX no corticos-
teroids were needed after 1 month of pamidronate ther-
apy and there are no clinical signs of the disease activity
now. In 1 patient treated with pamidronate and MTX
the dose of corticosteroids has significantly decreased.
No adverse event was observed.
Conclusion
In accordance with previous observations of other
authors the results of our small case series indicate
good efficacy of pamidronate treatment in patients with
CRMO. In contrast, MTX alone had no benefit in our
patients. We recommend considering pamidronate a
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